Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation

BackgroundEpigenetic changes associated with promoter DNA methylation results in silencing of several tumor suppressor genes that lead to increased risk for tumor formation and for progression of the cancer.MethodsMethylation specific PCR (MSP) and bisulfite sequencing were used for determination of proapoptotic gene Caspase 8 (CASP8) and the tumor suppressor gene maspin promoter methylation in four breast cancer and two non-tumorigenic breast cell lines. Involvement of histone H3 methylation in those cell lines were examined by CHIP assay.ResultsThe CpG sites in the promoter region of CASP8 and maspin were methylated in all four breast cancer cell lines but not in two non-tumorigenic breast cell lines. Demethylation agent 5-aza-2'-deoxycytidine (5-aza-dc) selectively inhibits DNA methyltransferases, DNMT3a and DNMT3b, and restored CASP8 and maspin gene expression in breast cancer cells. 5-aza-dc also reduced histone H3k9me2 occupancy on CASP8 promoter in SKBR3cells, but not in MCF-7 cells. Combination of histone deacetylase inhibitor Trichostatin A (TSA) and 5-aza-dc significant decrease in nuclear expression of Di-methyl histone H3-Lys27 and slight increase in acetyl histone H3-Lys9 in MCF-7 cells. CASP8 mRNA and protein level in MCF-7 cells were increased by the 5-aza-dc in combination with TSA. Data from our study also demonstrated that treatment with 5-FU caused a significant increase in unmethylated CASP8 and in CASP8 mRNA in all 3 cancer lines.ConclusionsCASP8 and maspin expression were reduced in breast cancer cells due to promoter methylation. Selective application of demethylating agents could offer novel therapeutic opportunities in breast cancer.

[1]  M. Manns,et al.  The Human Caspase-8 Promoter Sustains Basal Activity through SP1 and ETS-like Transcription Factors and Can Be Up-regulated by a p53-dependent Mechanism* , 2003, Journal of Biological Chemistry.

[2]  Howard Y. Chang,et al.  A histone H3 lysine 27 demethylase regulates animal posterior development , 2007, Nature.

[3]  Danny Reinberg,et al.  Histone Lysine Demethylases and Their Impact on Epigenetics , 2006, Cell.

[4]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[5]  C. Kitanaka,et al.  Apoptosis in cancer. , 1996, Human cell.

[6]  M. Hendrix,et al.  Biological functions of maspin , 2006, Journal of cellular physiology.

[7]  D. Park,et al.  The Cables gene on chromosome 18q is silenced by promoter hypermethylation and allelic loss in human colorectal cancer. , 2007, The American journal of pathology.

[8]  Zhengxin Wang,et al.  A novel function of caspase‐8 in the regulation of androgen‐receptor‐driven gene expression , 2007, EMBO Journal.

[9]  John Calvin Reed.  Mechanisms of apoptosis avoidance in cancer. , 1999, Current opinion in oncology.

[10]  C. Allis,et al.  In vivo cross-linking and immunoprecipitation for studying dynamic Protein:DNA associations in a chromatin environment. , 1999, Methods.

[11]  Anna Tesei,et al.  Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines , 2005, Breast Cancer Research.

[12]  S. Sethi,et al.  Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. , 2007, Archives of otolaryngology--head & neck surgery.

[13]  L. Rorke,et al.  Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  R K Gordon,et al.  S‐Adenosylmetliionine and methylation , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  M. Hendrix,et al.  Epigenetic silencing of maspin gene expression in human breast cancers , 2000, International journal of cancer.

[16]  N. Davidson,et al.  DNA methylation in breast cancer. , 2001, Endocrine-related cancer.

[17]  A. Wolffe,et al.  Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Martin Widschwendter,et al.  Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. , 2006, Cancer research.

[19]  L. Hood,et al.  Activation of the NF-kappaB pathway by caspase 8 and its homologs. , 2000, Oncogene.

[20]  F. Bazzoli,et al.  Frequent loss of hMLH1 by promoter hypermethylation leads to microsatellite instability in adenomatous polyps of patients with a single first-degree member affected by colon cancer. , 2003, Cancer research.

[21]  J. Herman,et al.  Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. , 1999, Cancer research.

[22]  T. Pandita,et al.  High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Korsmeyer,et al.  Errors of homeostasis and deregulated apoptosis. , 1997, Current opinion in genetics & development.

[24]  J. Strouboulis,et al.  Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription , 1998, Nature Genetics.

[25]  Domenech Js,et al.  Three molecular determinants of malignant conversion and their potential as therapeutic targets. , 1999 .

[26]  J. Herman,et al.  Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells , 2001 .

[27]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[28]  O. Olopade,et al.  Estrogen receptor α, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers , 2007, Breast Cancer Research and Treatment.

[29]  B. Brumback,et al.  Methylation of CASP8, DCR2, and HIN-1 in Neuroblastoma Is Associated with Poor Outcome , 2007, Clinical Cancer Research.

[30]  J. Herman,et al.  E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. , 1995, Cancer research.

[31]  S. Toyooka,et al.  Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. , 2002, Cancer research.

[32]  S. Fulda,et al.  IFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway , 2002, Oncogene.

[33]  Long-Cheng Li,et al.  MethPrimer: designing primers for methylation PCRs , 2002, Bioinform..

[34]  M. Hendrix,et al.  Maspin Regulates Different Signaling Pathways for Motility and Adhesion in Aggressive Breast Cancer Cells , 2003, Cancer biology & therapy.

[35]  H. Nagai,et al.  Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability. , 2001, Gastroenterology.

[36]  L. Ricci-Vitiani,et al.  Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. , 2005, Cancer research.

[37]  Martin Widschwendter,et al.  DNA methylation and breast carcinogenesis , 2002, Oncogene.

[38]  I. Jeremias,et al.  Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells , 2008, Oncogene.

[39]  L. Hood,et al.  Activation of the NF-κB pathway by Caspase 8 and its homologs , 2000, Oncogene.

[40]  O. Volpert,et al.  Maspin is an angiogenesis inhibitor , 2000, Nature Medicine.

[41]  R. Bast,et al.  Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. , 2003, Cancer research.

[42]  J. Schouten,et al.  Sequential gene promoter methylation during HPV-induced cervical carcinogenesis , 2007, British Journal of Cancer.

[43]  Ming Zhang,et al.  Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins , 2005, BMC Cancer.

[44]  Z. Khalkhali‐Ellis.  Maspin: The New Frontier , 2006, Clinical Cancer Research.

[45]  P. Spellman,et al.  Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities , 2008, BMC Cancer.

[46]  F. Behm,et al.  Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN , 2000, Nature Medicine.

[47]  J. Herman,et al.  Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.

[48]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[49]  G. Salvesen.  Caspase 8: igniting the death machine. , 1999, Structure.

[50]  Gabriele Schackert,et al.  CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. , 2007, Carcinogenesis.

[51]  Susan J Clark,et al.  DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. , 2008, Gynecologic oncology.

[52]  J. Roberts,et al.  The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. , 2007, The Journal of urology.

[53]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[54]  S. Sheng.  The promise and challenge toward the clinical application of maspin in cancer. , 2004, Frontiers in bioscience : a journal and virtual library.